News Releases - NervGen Pharma
WEBAug 2, 2024 · NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Homepage - NervGen Pharma
WEBAug 22, 2024 · NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th …
WEB1 day ago · Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions ...
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ).
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen (TSXV: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due...
NervGen Pharma’s NVG-291-R Demonstrates Significant
WEBJul 28, 2022 · NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis ...
NervGen Pharma Announces Intent to Conduct ... - Business Wire
WEBJan 10, 2022 · Following completion of the Phase 1 study in healthy males and the premonopausal females, NervGen intends to proceed to the planned Phase 1b/2 safety and efficacy studies in spinal cord injury ...
NervGen Pharma on Track to Complete Enrollment, Deliver Data …
WEBFeb 15, 2024 · NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it is on track to complete...
NervGen Completes Dosing Group With MS Candidate NVG-291
WEBNov 18, 2022 · A Phase 1 trial testing NVG-291, NervGen Pharma’s candidate for MS, has completed dosing in the final group of healthy postmenopausal women.
NervGen Cleared to Enroll Final Group in Trial of NVG-291
WEBMay 13, 2022 · NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an...
Skip to content